SOSV

Sharper Sense develops wearable neurotechnology to enhance vision, hearing, and touch. The company focuses on a neuromodulation patch that delivers non-invasive electrical stimulation to improve sensory acuity and perception, with potential applications for processing disorders and sensory loss, and to boost performance, enabling clearer, more accurate perceptions for improved task precision and safety.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Ostoform is a Dublin, Ireland-based medical device company focused on ostomy skin health. It develops patented devices designed to manage skin complications for ostomy patients, including OSTOFORM, a mouldable seal that wraps around the stoma, and FLOWASSIST, which directs stoma output away from the skin. The technology is designed to prevent skin contact with corrosive output, reduce leakage, and improve skin health. The business originated as a spin-out from the University of Limerick and was established in 2016, leveraging patented technology to scale its solutions globally.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Founded in 2021, Samphire Neuroscience specializes in developing neurotechnological solutions for women's health. Its flagship product is a non-invasive headband device that uses electrical neuromodulation to alleviate symptoms such as pain, fatigue, and mood changes associated with menstrual cycles.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Unlocked Labs develops targeted probiotics designed to manage specific health conditions. Their first product focuses on reducing kidney stone risk by digesting a stone-forming compound found in healthy foods like leafy vegetables.

BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. Its lead product, a first-in-class non-invasive eyedrop, aims to replace invasive injections for conditions like age-related macular degeneration and diabetic macular edema.

Synplexity is a biotechnology company located in New Castle, Delaware, specializing in mutational scanning and multiplexed gene synthesis through advanced artificial intelligence technology. The company operates a large-scale gene synthesis and proteomics discovery platform that utilizes microdroplets as microreactors. This innovative approach allows for the efficient creation of multiplex gene libraries, which have applications across various sectors, including therapeutics, biomanufacturing, agriculture, and climate systems. Synplexity aims to drive advancements in healthcare and other industries through its cutting-edge genetic technologies.

Founded in 2022 and headquartered in Berkeley, California, Laguna Bio develops a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of bispecific antibody drugs.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Asta Bio is a biotechnology company specializing in the development of radiotherapeutics for cancer treatment. It focuses on combining the alpha-emitting radioisotope 211-Astatine with multivalent single-domain antibodies to deliver targeted alpha radiation to tumor cells, sparing healthy cells. This approach aims to effectively destroy cancer cells by breaking their DNA strands.

Tinkeso Therapeutics is a biotechnology company specializing in the development of innovative, off-the-shelf cell therapies for treating cancer and autoimmune diseases. The company focuses on creating allogeneic chimeric antigen receptor (CAR) engineered natural killer T (NKT) cell therapies, which use NKT cells to target and destroy cancer cells or modulate the immune response in autoimmune conditions. This approach aims to increase treatment accessibility and scalability by utilizing non-patient-specific cells.

CellCo provides next generation biologics and biotherapies by integrating synthetic biology and AI.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. Its lead product, a first-in-class non-invasive eyedrop, aims to replace invasive injections for conditions like age-related macular degeneration and diabetic macular edema.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

Cell BioEngines is a clinical-stage biotechnology company specializing in developing 'off-the-shelf' stem cell therapies as drugs for treating human diseases. The company's core platform enables the production of high-quality, pure, and potent cell products at scale using a universal blood stem cell-derived technology.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Founded in 2021, Samphire Neuroscience specializes in developing neurotechnological solutions for women's health. Its flagship product is a non-invasive headband device that uses electrical neuromodulation to alleviate symptoms such as pain, fatigue, and mood changes associated with menstrual cycles.

XN Health is a medical device company founded in 2021 and based in Texas, USA. The company focuses on developing innovative healthcare solutions to assist mechanically ventilated patients in weaning off ventilators more efficiently. Its primary product utilizes phrenic nerve stimulation to induce diaphragm contractions, thereby mitigating the risks of diaphragm dysfunction associated with prolonged mechanical ventilation. By enhancing the weaning process, XN Health aims to improve patient outcomes and facilitate recovery in critical care settings.

Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the development of treatments for complex diseases such as cancer and age-related disorders.

Unlocked Labs develops targeted probiotics designed to manage specific health conditions. Their first product focuses on reducing kidney stone risk by digesting a stone-forming compound found in healthy foods like leafy vegetables.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

BryoSphere is a company specializing in the manufacturing of specialty chemicals, employing moss plants and biotechnology methods in the production of their goods. The company is currently focused on the development of two key products: one for addressing skin hyperpigmentation in topical treatments, and another as an anti-cancer drug.

Cell BioEngines is a clinical-stage biotechnology company specializing in developing 'off-the-shelf' stem cell therapies as drugs for treating human diseases. The company's core platform enables the production of high-quality, pure, and potent cell products at scale using a universal blood stem cell-derived technology.

Liberum Biotech is a biotechnology company focused on advancing protein manufacturing through proprietary molecular and hardware technologies. Its platform facilitates the rapid production of enzymes, therapeutics, and laboratory reagents, enabling clients to enhance speed and scalability while significantly reducing costs. By leveraging its innovative protein synthesizers, Liberum aims to democratize access to synthetic biology, ultimately transforming existing biologics manufacturing practices and making these technologies more accessible to a broader range of users.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. Its lead product, a first-in-class non-invasive eyedrop, aims to replace invasive injections for conditions like age-related macular degeneration and diabetic macular edema.

TippingPoint Biosciences is developing therapeutics that target abnormal DNA packaging states in diseases such as cancer.

Founded in 2019, Karma Biotechnologies is a Los Angeles-based company dedicated to developing therapies for autoimmune diseases, allergies, and food sensitivities. It specializes in antigen-specific immunotherapies using lipid nanoparticle engineering.

Founded in 2021, Samphire Neuroscience specializes in developing neurotechnological solutions for women's health. Its flagship product is a non-invasive headband device that uses electrical neuromodulation to alleviate symptoms such as pain, fatigue, and mood changes associated with menstrual cycles.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles engineered to signal through validated targets. Diadem's therapeutic platform aims to treat a variety of chronic inflammatory conditions, autoimmune diseases, and cancers. By focusing on the genetic engineering, manufacturing, and purification of these exosomes, Diadem provides innovative solutions for clinicians to effectively address immunopathologies and improve patient outcomes.

Pear Bio is a biotechnology company based in Boston and London. It develops precision medicine-guided therapeutics for hard-to-treat cancers using AI. The company analyzes tumor biopsies and blood to identify new targets, then tests drug candidates directly on patient samples using its proprietary immune-microtumor system.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

Cell BioEngines is a clinical-stage biotechnology company specializing in developing 'off-the-shelf' stem cell therapies as drugs for treating human diseases. The company's core platform enables the production of high-quality, pure, and potent cell products at scale using a universal blood stem cell-derived technology.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

Pear Bio is a biotechnology company based in Boston and London. It develops precision medicine-guided therapeutics for hard-to-treat cancers using AI. The company analyzes tumor biopsies and blood to identify new targets, then tests drug candidates directly on patient samples using its proprietary immune-microtumor system.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Spindle Biotech Inc., founded in 2017 and headquartered in Toronto, Canada, specializes in the development and commercialization of synthetic RNA technologies. The company focuses on a proprietary RNA polymerase that enhances large-scale mRNA vaccine production, reflecting the increasing relevance of synthetic RNA in biotechnological applications. Leveraging advances in mRNA technology, Spindle Biotech aims to facilitate high-throughput ribonucleoprotein (RNP)-based CRISPR and RNA screening. Utilizing advanced enzymes and microfluidic technology, it creates RNA arrays with high fidelity, which are vital for gene-editing and drug discovery initiatives. Through these innovations, Spindle Biotech seeks to support biotechnology companies in harnessing the transformative potential of synthetic RNA.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Founded in 2022 and headquartered in Berkeley, California, Laguna Bio develops a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of bispecific antibody drugs.

Filtricine is a Santa Clara, California-based biotechnology company focused on cancer therapy through targeted nutrient depletion. The company develops approaches that remove nutrients critical to cancer cell growth, enabling exploitation of cancer-specific metabolic dependencies without traditional drug substances. Through a nutrient modulation platform, Filtricine aims to identify metabolic vulnerabilities in cancers and apply strategies to deprive tumor cells of essential nutrients, potentially slowing or stopping disease progression. Founded in 2017, Filtricine operates as a clinical-stage, venture-backed biotechnology company dedicated to developing therapies that spare normal cells while targeting cancer metabolism.

Founded in 2021, Samphire Neuroscience specializes in developing neurotechnological solutions for women's health. Its flagship product is a non-invasive headband device that uses electrical neuromodulation to alleviate symptoms such as pain, fatigue, and mood changes associated with menstrual cycles.

Dandelion is a therapeutic company that focuses on training AI models that can design organ and cell-type-specific drug delivery vehicles. Dandelion was founded in 2022.

Chronos DX is a biotechnology research company based in London, Germany, specializing in drug development and in vitro diagnostics within the healthcare sector. The company is known for its innovative bioassay technology, which is designed for diagnostics, drug screening, and development. Chronos DX focuses on creating high-performance, low-cost, and scalable technology capable of detecting a variety of biomarkers, including cell-free DNA, micro proteins, exosomes, and metabolites. This technology provides medical professionals with a platform for in-line and in vivo monitoring of biomarkers, enhancing the capabilities of diagnostics and drug development in medical practice.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Kinexcs is an AI-driven health technology company focused on improving mobility and quality of life for individuals with musculoskeletal conditions. It offers a digital therapy solution comprising KIMIA, the world's first continuous knee health monitor, and an AI-based digital therapist for convenient and cost-effective access to therapy.

Founded in 2019, Kalia Health is a biotechnology company based in Chapel Hill, North Carolina. It develops affordable and accessible home-based early detection tests to improve maternal health outcomes.

Zennea Technologies is a medical device company based in Surrey, Canada, specializing in the development of therapeutic wearables aimed at reducing snoring and improving overall health through enhanced sleep quality. The company's flagship product, ZENS, is a comfortable and discreet sleep wearable that targets the root cause of snoring, thereby assisting individuals with chronic snoring and mild obstructive sleep apnea. Zennea conducts clinical trials to validate the efficacy of its device, which not only helps reduce snoring but also tracks sleep quality, providing valuable insights for users to make informed decisions about their health and sleep habits.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Founded in 2019, Kalia Health is a biotechnology company based in Chapel Hill, North Carolina. It develops affordable and accessible home-based early detection tests to improve maternal health outcomes.

Founded in 2020, Conan MedTech specializes in developing rapid point-of-care diagnostic tests for concussions. Its innovative technology enables sports medicine professionals and coaches to make informed decisions on the sideline during games, revolutionizing mild traumatic brain injury diagnosis.

Founded in 2020, Conan MedTech specializes in developing rapid point-of-care diagnostic tests for concussions. Its innovative technology enables sports medicine professionals and coaches to make informed decisions on the sideline during games, revolutionizing mild traumatic brain injury diagnosis.

Proteinea develops a protein engineering platform that uses proprietary AI models and computational tools to design next-generation antibodies with enhanced efficacy, safety, and convenience. The company aims to make biotherapeutics development smarter, safer, and faster.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

VemiCo is a biotechnology company focused on extending healthy living by addressing the aging process. The company leverages artificial intelligence and synthetic biology to discover and advance promising molecules derived from gut microbial DNA. By harnessing the potential of microbiomes, VemiCo aims to enhance gut health and overall well-being, offering innovative solutions for medical professionals in the health sector.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.

Founded in 2021, Samphire Neuroscience specializes in developing neurotechnological solutions for women's health. Its flagship product is a non-invasive headband device that uses electrical neuromodulation to alleviate symptoms such as pain, fatigue, and mood changes associated with menstrual cycles.

Unlocked Labs develops targeted probiotics designed to manage specific health conditions. Their first product focuses on reducing kidney stone risk by digesting a stone-forming compound found in healthy foods like leafy vegetables.

XN Health is a medical device company founded in 2021 and based in Texas, USA. The company focuses on developing innovative healthcare solutions to assist mechanically ventilated patients in weaning off ventilators more efficiently. Its primary product utilizes phrenic nerve stimulation to induce diaphragm contractions, thereby mitigating the risks of diaphragm dysfunction associated with prolonged mechanical ventilation. By enhancing the weaning process, XN Health aims to improve patient outcomes and facilitate recovery in critical care settings.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can either inhibit or promote ferroptosis, a form of regulated cell death. By targeting this mechanism, Prothegen seeks to provide effective therapeutics that can prevent unwanted cell death, thereby improving treatment options for various diseases.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can either inhibit or promote ferroptosis, a form of regulated cell death. By targeting this mechanism, Prothegen seeks to provide effective therapeutics that can prevent unwanted cell death, thereby improving treatment options for various diseases.

Ostoform is a Dublin, Ireland-based medical device company focused on ostomy skin health. It develops patented devices designed to manage skin complications for ostomy patients, including OSTOFORM, a mouldable seal that wraps around the stoma, and FLOWASSIST, which directs stoma output away from the skin. The technology is designed to prevent skin contact with corrosive output, reduce leakage, and improve skin health. The business originated as a spin-out from the University of Limerick and was established in 2016, leveraging patented technology to scale its solutions globally.

Intelligent Implants is a bioelectronics company developing an implantable electrical stimulation platform that uses wireless devices to stimulate, steer, and monitor bone growth and tissue recovery. The company designs electrotherapeutic medical devices intended to treat diseases and accelerate healing in bone and other tissues. Its implants enable healthcare providers to control and monitor treatment, supporting decision making in patient care. By integrating data, engineering and medicine, Intelligent Implants aims to bring active, connected medical devices to clinical practice, improving outcomes for individuals with bone conditions and related injuries.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Pear Bio is a biotechnology company based in Boston and London. It develops precision medicine-guided therapeutics for hard-to-treat cancers using AI. The company analyzes tumor biopsies and blood to identify new targets, then tests drug candidates directly on patient samples using its proprietary immune-microtumor system.

Founded in 2019, Karma Biotechnologies is a Los Angeles-based company dedicated to developing therapies for autoimmune diseases, allergies, and food sensitivities. It specializes in antigen-specific immunotherapies using lipid nanoparticle engineering.

Microgenesis is a biotechnology company focused on fertility and pregnancy health monitoring. It has developed a platform that provides a non-invasive fertility test and personalized nutritional supplementation aimed at restoring women's fertility potential. The company's innovative diagnostic approach detects subclinical inflammation that negatively impacts ovarian function and implantation, specifically targeting women who have experienced challenges, including multiple failed IVF attempts. Operating out of a CLIA lab in Oakland, Microgenesis offers its solutions through OB-GYNs and direct-to-consumer channels. Additionally, the platform addresses imbalances in vaginal and intestinal microbiota linked to infertility and offers dual testing for immunological issues related to the endometrium, equipping patients with effective treatment options for complex reproductive health cases.

Filtricine is a Santa Clara, California-based biotechnology company focused on cancer therapy through targeted nutrient depletion. The company develops approaches that remove nutrients critical to cancer cell growth, enabling exploitation of cancer-specific metabolic dependencies without traditional drug substances. Through a nutrient modulation platform, Filtricine aims to identify metabolic vulnerabilities in cancers and apply strategies to deprive tumor cells of essential nutrients, potentially slowing or stopping disease progression. Founded in 2017, Filtricine operates as a clinical-stage, venture-backed biotechnology company dedicated to developing therapies that spare normal cells while targeting cancer metabolism.

Founded in 2020, Advanced Microbubbles specializes in developing microbubble technology for targeted drug delivery. Utilizing ultrasound, the company's products temporarily open barriers like the blood-brain barrier to facilitate local drug entry, enhancing precision and reducing side effects.